Please sign in to follow a disease.
Can rewriting traumatic images ease psychosis?
NCT ID NCT06539780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a therapy called imagery rescripting in 8 people with early psychosis. Participants imagine a different, more positive outcome to their traumatic memories. The goal is to see if this improves core beliefs, wellbeing, and self-esteem. It is a very small, early-phase trial with no control group.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Imagery Rescripting (a behavioral therapy where patients imagine a different, more positive sequence of events related to their trauma)
- What this could lead to
- If it works, this could point toward a new therapy to ease trauma-related beliefs and improve wellbeing in early psychosis.
- What could go wrong
- This is a very small, early-phase study with only 8 participants and no control group. Results may not apply to everyone, and the therapy might not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 8 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
16 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Meet the criteria for schizophrenia spectrum disorder, a primary diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders (5th ed; American Psychiatric Association, 2013) * Preferably Dutch literacy, as exception English literacy is allowed if the practitioner is able to provide treatment * Preferably stable in medication at start. Exclusion Criteria: * Current mania * Active suicidal plans * Current alcohol or drugs abuse as diagnosed by DSM-5, use is permitted if not significantly influencing treatment outcomes. * Neurological disorder
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Psychoses, traumatic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam UMC
Amsterdam-Zuidoost, North Holland, 1105 AZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Scientists build a computer model of the brain to explain hearing voices
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial